Diagnostic value of 18F-labeled NaF positron emission tomography-computed tomography imaging in the detection of bone metastases in patients with lung cancer before treatment

National Medical Journal of China

Volumn 92, Issue 35, 2012, Pages 2495-2498

  Wang, Xiao Yan ^a   Rao, Liang Jun ^a   Luo, Bing Qi ^a   Chen, Zhi Feng ^a   Zhang, Xiang Song ^a   Shi, Xin Chong ^a   Yi, Chang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Lung neoplasms; Neoplasm metastasis; Positron emission tomography

Indexed keywords

SODIUM FLUORIDE F 18;

ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; PREOPERATIVE PERIOD; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84869773322     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2012.35.013     Document Type: Article

References (13)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin, 2011, 61:212-236.
2. 2005, 8:274-278.
3. Park J Y, Kim K Y, Lee J, et al. Impact of abnormal uptakes in bone scan on the prognosis of patients with lung cancer. Lung Cancer, 2000, 28:55-62.
4. Tsuya A, Kurata T, Tamura K, et al. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer, 2007, 57:229-232.
5. Blake G M, Park-Holohan S J, Cook G J, et al. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med, 2001, 31:28-49.
6. Kawaguchi M, Tateishi U, Shizukuishi K, et al. 18F-fluoride uptake in bone metastasis: morphologic and metabolic analysis on integrated PET/CT. Ann Nucl Med, 2010, 24:241-247.
7. Erturan S, Yaman M, Aydin G, et al. The role of whole-body bone scanning and clinical factors in detecting bone metastases in patients with non-small cell lung cancer. Chest, 2005, 127:449-454.
8. Min J W, Um S W, Yim J J, et al. The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer. J Korean Med Sci, 2009, 24:275-280.
9. Ndlovu X, George R, Ellmann A, et al. Should SPECT-CT replace SPECT for the evaluation of equivocal bone scan lesions in patients with underlying malignancies? Nucl Med Commun, 2010, 31:659-665.
10. Silvestri G A, Tanoue L T, Margolis M L, et al. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest, 2003, 123:147S-156S.
11. Silvestri G A, Gould M K, Margolis M L, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest, 2007, 132:178S-201S.
12. Cook G J, Houston S, Rubens R, et al. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol, 1998, 16: 3375-3379.
13. Schirrmeister H, Glatting G, Hetzel J, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18) F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med, 2001, 42:1800-1804.